Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9168238 | FRESENIUS KABI USA | Levothyroxine formulations |
Aug, 2032
(8 years from now) | |
US9168239 | FRESENIUS KABI USA | Levothyroxine formulations |
Aug, 2032
(8 years from now) | |
US9006289 | FRESENIUS KABI USA | Levothyroxine formulations |
Oct, 2032
(8 years from now) | |
US9782376 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(12 years from now) | |
US11135190 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(12 years from now) | |
US10398669 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(12 years from now) |
Levothyroxine Sodium is owned by Fresenius Kabi Usa.
Levothyroxine Sodium contains Levothyroxine Sodium.
Levothyroxine Sodium has a total of 6 drug patents out of which 0 drug patents have expired.
Levothyroxine Sodium was authorised for market use on 24 June, 2011.
Levothyroxine Sodium is available in solution;intravenous, powder;intravenous dosage forms.
The generics of Levothyroxine Sodium are possible to be released after 01 December, 2036.
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 24 June, 2011
Treatment: NA
Dosage: POWDER;INTRAVENOUS; SOLUTION;INTRAVENOUS
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11154498 | HIKMA | Stabilized liquid formulation of levothyroxine |
Jul, 2036
(12 years from now) |
Levothyroxine Sodium is owned by Hikma.
Levothyroxine Sodium contains Levothyroxine Sodium.
Levothyroxine Sodium has a total of 1 drug patent out of which 0 drug patents have expired.
Levothyroxine Sodium was authorised for market use on 17 May, 2021.
Levothyroxine Sodium is available in solution;intravenous dosage forms.
The generics of Levothyroxine Sodium are possible to be released after 20 July, 2036.
Drugs and Companies using LEVOTHYROXINE SODIUM ingredient
Market Authorisation Date: 17 May, 2021
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS